Abstract:Hepatitis B virus (HBV) infection is the leading cause of chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC). This study reveals a distinct mechanism underlying the regulation of HBV replication. HBV activates homeobox A10 (HoxA10) in human hepatocytes, leukocytes, peripheral blood mononuclear cells (PBMCs), HepG2-NTCP cells, leukocytes isolated from CHB patients, and HBV-associated HCC tissues. HoxA10 in turn represses HBV replication in human hepatocytes, HepG2-NTCP cells, and BALB/c mice. Interestingly, we show that during early HBV infection, p38 mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) were activated to facilitate HBV replication; however, during late HBV infection, HoxA10 was induced to attenuate HBV replication. Detailed studies reveal that HoxA10 binds to p38 MAPK, recruits SH2-containing protein tyrosine phosphatase 1 (SHP-1) to facilitate SHP-1 in catalyzing dephosphorylation of p38 MAPK/STAT3, and thereby attenuates p38 MAPK/STAT3 activation and HBV replication. Furthermore, HoxA10 binds to the HBV enhancer element I (EnhI)/X promoter, competes with STAT3 for binding of the promoter, and thereby represses HBV transcription. Taken together, these results show that HoxA10 attenuates HBV replication through repressing the p38 MAPK/STAT3 pathway by two approaches: HoxA10 interacts with p38 MAPK and recruits SHP-1 to repress HBV replication, and HoxA10 binds to the EnhI/X promoter and competes with STAT3 to attenuate HBV transcription. Thus, the function of HoxA10 is similar to the action of interferon (IFN) in terms of inhibition of HBV infection; however, the mechanism of HoxA10-mediated repression of HBV replication is different from the mechanism underlying IFN-induced inhibition of HBV infection. IMPORTANCE Two billion people have been infected with HBV worldwide; about 240 million infected patients developed chronic hepatitis B (CHB), and 650,000 die each year from liver cirrhosis (LC) or hepatocellular carcinoma (HCC). This work elucidates a mechanism underlying the control of HBV replication. HBV infection activates HoxA10, a regulator of cell differentiation and cancer progression, in human cells and patients with CHB and HCC. HoxA10 subsequently inhibits HBV replication in human tissue culture cells and mice. Additionally, HoxA10 interacts with p38 MAPK to repress the activation of p38 MAPK and STAT3 and recruits and facilitates SHP-1 to catalyze the dephosphorylation of p38 MAPK and STAT3. Moreover, HoxA10 competes with STAT3 for binding of the HBV X promoter to repress HBV transcription. Thus, this work reveals a negative regulatory mechanism underlying the control of HBV replication and provides new insights into the development of potential agents to control HBV infection.

The proteasome activator subunit PSME1 promotes HBV replication by inhibiting the degradation of HBV core protein

Deubiquitinase OTUD5 Promotes Hepatitis B Virus Replication by Removing K48-linked Ubiquitination of HBV core/precore and Up-regulating HNF4ɑ Expressions through Inhibiting the ERK1/2 /Mitogen-activated Protein Kinase Pathway

PreS1BP mediates inhibition of Hepatitis B virus replication by promoting HBx protein degradation

Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation.

Restriction of hepatitis B virus replication by c-Abl-induced proteasomal degradation of the viral polymerase.

Human Hepatitis B Virus X Protein Promotes Cell Proliferation and Inhibits Cell Apoptosis Through Interacting with a Serine Protease Hepsin.

Abstract 4891: Hepatitis B Virus Remodels Host Protein Interaction Networks to Generate Distinct Cellular Dependencies

Identification and characterization of host factor VCPIP1 as a multi-functional positive regulator of hepatitis B virus

Hepatitis C virus core protein inhibits hepatitis B virus replication by downregulating HBx levels via Siah-1-mediated proteasomal degradation during coinfection

HBV PreC interacts with SUV39H1 to induce viral replication by blocking the proteasomal degradation of viral polymerase

Aerobic glycolysis supports hepatitis B virus protein synthesis through interaction between viral surface antigen and pyruvate kinase isoform M2

Hepatitis B virus core protein as a Rab-GAP suppressor driving liver disease progression

HoxA10 Facilitates SHP-1-Catalyzed Dephosphorylation of P38 MAPK/STAT3 to Repress Hepatitis B Virus Replication by a Feedback Regulatory Mechanism

Ceruloplasmin Inhibits the Production of Extracellular Hepatitis B Virions by Targeting Its Middle Surface Protein

HBx-Derived Constrained Peptides Inhibit the Secretion of Hepatitis B Virus Antigens

Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion

Hepatitis B virus X protein inhibits apoptosis by modulating endoplasmic reticulum stress response.

PRMT5 Restricts Hepatitis B Virus Replication Through Epigenetic Repression of Covalently Closed Circular DNA Transcription and Interference with Pregenomic RNA Encapsidation

Hepatitis B Virus HBx Protein Interactions with the Ubiquitin Proteasome System

Interactome Map Reveals Phospholipid Scramblase 1 As a Novel Regulator of Hepatitis B Virus X Protein

The Hepatitis B Virus X Protein Disrupts Innate Immunity by Downregulating Mitochondrial Antiviral Signaling Protein